PNR-3-80
Based on 1 Customer Validation
PNR-3-80 is an endonuclease G (ENDOG) inhibitor with an IC50 of 0.67 μM. As a non-competitive binder to the ENDOG-substrate complex, PNR-3-80 specifically inhibits the endonuclease activity of ENDOG. PNR-3-80 reduces cell death induced by Cisplatin (HY-17394) and Docetaxel (HY-B0011), and inhibits DNA damage and autophagy (autophagy) induced by Etoposide (HY-13629). PNR-3-80 can be used in studies related to cell injury.
For research use only. We do not sell to patients.
- CAS No.: 1424353-63-8
- Formula: C24H14ClN3O3S
- Molecular Weight:459.90
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
PNR-3-80 (50 μM; 24 h) inhibits endonuclease G (ENDOG)-dependent DNA damage and autophagy induction in human hepatocytes[1].
PNR-3-80 potently inhibits recombinant mouse EndoG in high-throughput luciferase reporter gene assays, with an IC50 of 0.67 μM[2].
PNR-3-80 (1 μM for 1 h against mouse EndoG; 1 mM for 1 h against human EndoG) protects plasmid DNA from degradation by EndoG in plasmid nicking assays[2].
PNR-3-80 (pre-incubated for 2 h followed by co-incubation with Cisplatin for 24 h at a concentration of 50 μM) significantly protects 22Rv1 human prostate cancer cells that endogenously express EndoG against Cisplatin-induced cell death[2].
PNR-3-80 (preincubated for 2 h followed by co-incubation with docetaxel for 24 h at a concentration of 50 μM) significantly protects human prostate adenocarcinoma PC3 cells overexpressing EndoG from Docetaxel (HY-B0011)-induced cell death and DNA fragmentation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human prostate carcinoma 22Rv1 cells
-
Concentration:50 μM
-
Incubation Time:2 h pre-incubation, followed by 24 h co-incubation with Cisplatin
-
Result:Significantly inhibited Cisplatin-induced LDH release, reducing Cisplatin-induced cell death compared to controls without inhibitor.
-
Cell Line:EndoG-overexpressing human prostate adenocarcinoma PC3 cells
-
Concentration:50 μM
-
Incubation Time:2 h pre-incubation, followed by 24 h co-incubation with Docetaxel
-
Result:Significantly inhibited Docetaxel-induced LDH release, reducing Docetaxel-induced cell death compared to controls without inhibitor.
Significantly decreased Docetaxel-induced DNA fragmentation as measured by TUNEL staining.
Chemical Information
-
CAS No. 1424353-63-8
-
Appearance Solid
-
Molecular Weight 459.90
-
Formula C24H14ClN3O3S
-
Color Light yellow to yellow
-
SMILES
O=C1NC(NC(/C1=C\C2=CN(C3=C2C=C(Cl)C=C3)C(C4=CC5=C(C=CC=C5)C=C4)=O)=O)=S
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang W, et al. Endonuclease G promotes autophagy by suppressing mTOR signaling and activating the DNA damage response. Nat Commun. 2021;12(1):476. Published 2021 Jan 20. [Content Brief]
[2]. Jang DS, et al. Novel cytoprotective inhibitors for apoptotic endonuclease G. DNA Cell Biol. 2015;34(2):92-100. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)